Dr John Barlow is the Principal Investigator for the CACOS Study, Australia’s largest medicinal cannabis observational trial. He has more than 10 years experience in clinical trials in a range of medical, surgical and public health fields, particularly oncology, neurology and orthopaedics. John is a former Associate Professor in the Department of Medicine at Monash University and was a Neil Hamilton Fairley Fellow of the National Health and Medical Research Council. He holds a PhD from Monash University and has published more than 200 peer reviewed papers and abstracts encompassing a range of topics including endocrinology, clinical chemistry and drug evaluation.
Dr Masego Tsimako Johnstone is a Research Lead for Applied Cannabis Research and has significant experience in biomedical and clinical research. She was a Fulbright Scholar at Baylor College of Medicine, Texas, USA. Masego was also a co-investigator for an NIH/H3 Africa funded research network known as the Collaborative African Genomics Network (CAfGEN) which primarily focused on addressing gene-environment interactions for HIV/AIDS and co-morbidities amongst African paediatric populations. Masego holds a PhD in Molecular Sciences from the University of Queensland and was a post-doctoral researcher at QIMR. She has also worked in the biotech sector and for contract research organisations within Australia focused on the delivery of sponsored Phase I-IV clinical trials and in-house observational studies. She brings this wealth of knowledge and expertise to ACR to deliver quality research programs to the medicinal cannabis sector.
Advisory board member
Dr Melissa Benson sits on the Applied Cannabis Research advisory board. She brings her experience and expertise in conducting clinical trials with medicinal cannabis products to the broader ACR team in an advisory capacity. Melissa holds a PhD in Neuropharmacology from the University of Queensland and has completed postdoctoral fellowships focused on drug development in the fields of refractory epilepsy and cannabinoids. She has also completed postgraduate studies in intellectual property commercialisation. Melissa has managed sites for registration level pharmaceutical clinical trials (outside of cannabis) and was previously Clinical team leader at the Lambert Initiative for Cannabinoid Therapeutics based at the University of Sydney, where she oversaw development, start-up, and execution of clinical trials with medicinal cannabinoids.
ACR receives funding from industry clients including but not limited to licensed medicinal cannabis producers and suppliers.
Many Australians with IBD use cannabis for symptom management – but their doctors aren’t convinced Two recently published surveys on inflammatory bowel disease (IBD) and